Forte Biosciences, Inc.
14.38+0.92 (+6.84%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · FBRX · USD
Key Stats
Market Cap
178.78MP/E (TTM)
-Basic EPS (TTM)
-3.68Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Forte Biosciences narrowed its Q2 operating loss to $11.6M from $12.8M y/y, driven by lower G&A expenses that offset higher R&D spending on FB102 trials, while net loss improved to $11.2M from $12.5M y/y (derived). For the half-year, operating expenses climbed 34% y/y to $27.7M, reflecting ramped-up clinical work, yielding a net loss of $26.9M versus $19.9M last year (derived). Cash swelled to $106.1M at quarter-end, bolstered by a $75M public offering in June—enough to fund operations through mid-2026. No debt burdens the balance sheet. Yet clinical setbacks could derail FB102's autoimmune promise.
8-K
Forte's Q2 loss, FB102 trials advance
Forte Biosciences reported Q2 2025 net loss of $11.2 million, with R&D expenses climbing to $8.5 million from $5.6 million year-over-year, fueled by FB102 clinical trials in celiac disease and vitiligo. The company raised $71.6 million via public offering, bolstering its cash position to $106.1 million. Three FB102 readouts loom in 2026. Clinical risks persist amid autoimmune uncertainties.
8-K
Forte prices $75M offering
Forte Biosciences priced a $75 million public offering on June 24, 2025, selling 5.63 million shares at $12.00 each and pre-funded warrants for 619,606 shares at $11.999, with underwriters holding a 30-day option for 937,508 more shares. Net proceeds of $70 million, or $80.5 million if fully exercised, will fund clinical development and operations into 2027. Yet market conditions could delay closing, set for June 26.
8-K
Positive FB102 celiac Phase 1b data
Forte Biosciences unveiled positive Phase 1b results for FB102 in celiac disease on June 23, 2025, showing statistically significant histological improvements—VCIEL score of 0.079 versus -1.849 for placebo (p=0.0099)—and a 42% reduction in gluten-induced GI symptoms, with no severe adverse events. The trial enrolled 32 subjects randomized 3:1, all completing the 16-day gluten challenge after four 10 mg/kg doses. Phase 2 initiates in 2H25, topline in 2026. Early data may not predict later trials.
8-K
Annual meeting elects directors
Forte Biosciences held its 2025 annual meeting on May 29, electing Richard Vincent, Shiv Kapoor, and David Gryska as Class II directors until 2028, with Vincent and Kapoor securing strong support while Gryska faced notable withheld votes. Stockholders overwhelmingly ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025. This routine governance approval signals board continuity amid biotech volatility.
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
FATE
Fate Therapeutics, Inc.
1.34-0.15
FBIO
Fortress Biotech, Inc.
2.52-0.04
FBLG
FibroBiologics, Inc.
0.39-0.03
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
LBRX
LB Pharmaceuticals Inc
15.65-0.92
SABS
SAB Biotherapeutics, Inc.
3.04+0.02
TVRD
Tvardi Therapeutics, Inc.
4.78+0.06
VTYX
Ventyx Biosciences, Inc.
7.37-0.01
XLO
Xilio Therapeutics, Inc.
0.81-0.01